Safety profiles of idelalisib, duvelisib and TGR-1202 in treating CLL
Jennifer Brown • 10 Aug 2017
Do CLL patients with mutated immunoglobulin receptors respond better to therapy?
Paolo Ghia • 11 Aug 2017
Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.